Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period.
Ishibashi
M
M
Department of Urology, Hyogo College of Medicine, Japan.
Miyamoto
S
S
Nojima
M
M
Yoshimoto
T
T
Yabumoto
H
H
Mori
Y
Y
Shima
H
H
D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008775:Methylprednisolone / Q000627:therapeutic use; D011184:Postoperative Period; D012263:Ribonucleosides / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016559:Tacrolimus; D008775:Methylprednisolone